

1 Hydroxychloroquine serum concentrations in non-critical care patients infected with  
2 SARS-CoV-2

3

4

5

6

7 Alasdair MacGowan<sup>1\*</sup>, Fergus Hamilton<sup>1</sup>, Mark Bayliss<sup>1</sup>, Liam Read<sup>1</sup>, Marie Attwood<sup>1</sup>,  
8 Alan Noel<sup>1</sup>, Sally Grier<sup>1</sup>, Anna Morley<sup>2</sup>, David Arnold<sup>2</sup>, Nicholas Maskell<sup>2</sup>

9

10

11

12 1. Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences,  
13 Pathology Sciences Building – Phase 2, Science Quarter, Southmead Hospital,  
14 Westbury-on-Trym, Bristol, BS10 5NB, UK

15

16

17

18 2. Academic Respiratory Unit, Second Floor, Learning & Research Building, Science  
19 Quarter, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK

20

21

22 \*Corresponding Author

23 e-mail: [alasdair.macgowan@nbt.nhs.uk](mailto:alasdair.macgowan@nbt.nhs.uk)

24 Tel: +44 (0) 117 414 6215

25

26 **Abstract**

27

28 Hydroxychloroquine(HCQ) has been widely used to treat SARS-CoV-2 infection however  
29 HCQ pharmacokinetics in this condition have not been studied in non-critical care patient  
30 groups. Here we report the serum concentrations of HCQ in a small cohort of patients  
31 treated with HCQ as part of the RECOVERY trial.

32

33 **Introduction**

34

35 Hydroxychloroquine (HCQ) has been widely used to treat infection with SARS-CoV-2 but  
36 most recently has been shown to be of no benefit in a large randomised clinical trial  
37 (RECOVERY 2020). Detailed information on the pharmacodynamics of HCQ is lacking but  
38 measures of the *in vitro* activity of HCQ against SARS-CoV-2 are available as well as  
39 pharmacokinetic data derived from analysis of patients with conditions other than  
40 SARS-CoV-2 infection who received HCQ. HCQ is much less active against SARS-CoV-2 *in*  
41 *vitro* than it is against Plasmodium species. Pharmacokinetic data from patients with  
42 SARS-CoV-2 is sparse and absent for those outside critical care (Perinel et al, 2020). Here we  
43 report data on the serum concentrations of HCQ in patients who were recruited into the  
44 Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial. Permission to take and use  
45 stored serum was ethically approved as part of the Diagnostic and Severity markers in  
46 COVID-19 to Enable Rapid triage (DISCOVER) Study. Patients received HCQ at a dose of  
47 800mg 6 hrly apart, then 400mg 6 hours later followed by 400mg 12 hrly subsequently.

48

49

50 **Methods and Results**

51

52 HCQ was assayed using a recently developed LC-MS/MS method. Serum was deproteinised  
53 with acetonitrile after addition of the internal standard, chloroquine. The method was  
54 validated over a working range of 0.005 to 1 mg/L. There was no evidence of drug loss in gel  
55 separated tubes compared to plain tubes or after 24 hr at room temperature. The mean  
56 blood/plasma partitioning ratio was  $1.64 \pm 0.25$ .

57

58 Seven patients were recruited into the HCQ treatment arm. Subsequently one patient  
59 (male, aged 58 years) had no blood samples drawn and a second (male, aged 84 years) only  
60 received a single dose of 800mg. Of the five remaining, two were male, three female with a  
61 mean  $\pm$  std (min-max) age of  $57.4 \pm 20.7$  (26-83) and weight of  $70.6 \pm 4.2$  (65.4-75.0) kgs. All  
62 had eGFRs  $>80$ ml/min on day 0 and none had serum bilirubin, alkaline phosphatase or  
63 alamase aminotransferase enzyme levels of more than three times normal. Three of the  
64 five had co-morbidities – that is, cardiac, neurological or neoplastic disease. All HCQ serum  
65 concentrations were  $\leq 0.005$ mg/L either before or on the first day of dosing. Serum  
66 concentrations on subsequent days after starting treatment are shown on Figure 1.

67

68 Concentrations on day 1, 2, 3 and 4 were  $0.4 \pm 0.35$ mg/L (n=3);  $0.43 \pm 0.14$ mg/L (n=3),  $0.46$   
69 mg/L (n=2), and  $0.62$ mg/L (n=2) respectively.

70

71 The timing of sampling after oral dose was variable –  $2.9 \pm 3.5$  (0.12-8.5 hours), though  
72 three quarters were taken within 4 hours of the dose being administered.

73

74 **Discussion**

75

76 Data on the pharmacokinetics of HCQ has been accumulated in patients with conditions  
77 other than SARS-CoV-2 infection. The European SmPC suggest that after a single 400mg  
78 dose, the peak serum concentration was 0.105mg/L at 1.8 hr post dose (SmPC, 2017).

79 Pharmacokinetic and modelling data exists for SARS-CoV-2 infected patients . Yoa et al,  
80 2020 simulated several potential doses of HCQ suggesting that in Chinese subjects (usually  
81 smaller and lighter than European or North American patients) that a dose of 400mg BD and  
82 200mg BD may be optimal. Interestingly, mean serum HCQ concentrations were not  
83 predicted to be >1mg/L until 4-5 days therapy with this regimen. Downes et al, 2020  
84 simulated doses more akin to those used in the RECOVERY trial – that is, 1600mg on day 1  
85 and 400mg/day thereafter. The predicted Cmax (IQR) was 2.7mg/L (2.2-3.3) and AUC  
86 109.9mg/L.h. Perinel et al, 2020 performed a study of HCQ serum concentrations in French  
87 patients in critical care receiving 200mg TDS; most were mechanically ventilated. It took 2-7  
88 days for serum concentration to reach 1mg/L. They also suggested a reference range of  
89 >1mg/L and <2mg/L but only 8 out of 13 patients reached these concentrations. HCQ  
90 dosing in the RECOVERY trial is higher than those in these studies and, despite this, all our  
91 patients, none of whom were receiving critical care, had HCQ concentration of <1mg/L. It  
92 may be expected that patients not receiving critical care may have better absorption than  
93 those in ICU.

94

95 There are a number of limitations of our study – most obviously, the small number of  
96 patients and samples available. However, our data indicates that HCQ concentrations are  
97 lower than might be expected, even with a high dose regimen.

98

99 Given that HCQ is likely to have marginal pharmacodynamics in SARS-CoV-2 infection, this  
100 data may in part help explain the lack of benefit in randomised clinical trials.

101

102 **Funding**

103 This study was supported by the Severn Infection Sciences Partnership, Southmead  
104 Research Foundation, and North Bristol NHS Trust.

105

106 **Transparency declarations**

107 Bristol Centre for Antimicrobial Research & Evaluation (BCARE) receives grant funding for  
108 research on antimicrobials from Paratek, Wockhardt, InfectoPharm, Venatorx, Merck,  
109 AiCURIS, NosoPharm, Evotec, IMI JU, COMBACTE MAGNET and GNA NOW, MRC(UK) and  
110 NIHR(UK).

111

112 **References**

113

114 Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY  
115 (RECOVERY) Trial on hydroxychloroquine, 5 June 2020.

116 <https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf>

117

118 Perinel S, Launay M, Botelho-Nevers E, Diconne E, Louf-durier A, Lachand R, Murgier M,  
119 Page D, Vermesch R, Thierry G, Delavanne X. Towards Optimization of Hydroxychloroquine  
120 Dosing in Intensive Care Unit COVID-19 Patients. *Clin Inf Dis* 2020 published online.

121 <https://doi:10.1093/cid/ciaa394/5816960>

122

123 Summary of Product Characteristics (SmPC). Quinoric 200mg Film-Coated Tablets 2017.

124 <https://www.medicines.org.uk/emc/product/477/smpc/print>

125

126 Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H,  
127 Tan W, Liu D. In vitro Antiviral Activity and Projection of Optimized Dosing Design of  
128 hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Corona virus  
129 2 (SARS-CoV-2). *Clin Inf Dis* 2020. <https://doi/10.1093/cid/ciaa237/5801998>

130

131 Downes KJ, Chiotos K, Fitzgerald JC, Scheetz MH, Zuppa AF. Rational Dosing of  
132 Hydroxychloroquine for the Treatment of COVID-19. *Open Science Framework PrePrints*

133 <https://osf.io/py3kv/>

134

135

FIGURE 1 Serum concentrations of hydroxyl chloroquine

